期刊
INTERNATIONAL JOURNAL OF ENDOCRINE ONCOLOGY
卷 3, 期 3, 页码 221-233出版社
FUTURE MEDICINE LTD
DOI: 10.2217/ije-2016-0007
关键词
anaplastic thyroid cancer; BRAF; case report; chemotherapy; dabrafenib; dedifferentiated; sarcomatoid; squamous; targeted therapy; trametinib; undifferentiated; vemurafenib
类别
Targeted therapies have played a major role in cancer therapeutics, starting with the discovery of a drug against BCR-ABL rearrangements in chronic myelogenous leukemia. This led to the first approval of a targeted agent in cancer and since, many others have followed. Anaplastic thyroid cancer (ATC) is an aggressive carcinoma with few curative options. Although previous cytotoxic chemotherapy and kinase inhibitor therapies have not proven efficacious in ATC, some of the newer drugs appear to be promising. A case report and a comprehensive review of the current standard of care, genetics, modern therapeutic drugs and clinical trials are presented, in order to outline where we currently stand and where the future lies in the quest for a cure for ATC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据